Karyopharm Therapeutics Inc. approved retention equity awards for three executive officers, including stock options for 137,500 shares and 68,750 restricted stock units, effective February 28, 2025, with specific vesting conditions.
AI Assistant
KARYOPHARM THERAPEUTICS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.